Boothbay Fund Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Boothbay Fund Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$588K	–	2062
2023 Q4	$588K	Buy	+10,000	New	+$562K	0.02%	926
2023 Q2	–	Sell	-6,196	Closed	-$230K	–	2482
2023 Q1	$230K	Sell	6,196 -14,040	-69%	-$631K	﹤0.01%	1657
2022 Q4	$917K	Buy	+20,236	New	+$1.31M	0.02%	933
2020 Q4	–	Sell	-4,066	Closed	-$879K	–	1473
2020 Q3	$675K	Buy	+4,066	New	+$556K	0.04%	560

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Boothbay Fund Management's MRTX Position: Q1 2024 in Review

Boothbay Fund Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 10,000 shares — an estimated $588K sold.

Boothbay Fund Management first reported a position in MRTX in Q3 2020 and held it in 4 quarters. The position peaked at $917K in Q4 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Boothbay Fund Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Boothbay Fund Management sold 10,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $588K.
Boothbay Fund Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
Boothbay Fund Management's Mirati Therapeutics, Inc. Common Stock position peaked at $917K in Q4 2022.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.